Bone Marrow Transplants: Cancer Drug Shows Promise Against Graft Vs. Host Disease
Wednesday, July 16, 2008 - 11:28
in Health & Medicine
A study in mice suggests the drug SAHA, a new antitumor drug, is also able to reduce the effects of graft-versus-host disease, a common, sometimes fatal complication of bone marrow transplants. SAHA and other HDAC inhibitors also may provide a new way to treat autoimmune diseases. Plans are under way for a U-M trial of the drug in people to prevent graft vs. host disease.
Read the whole article on Science Daily
More from Science Daily
Related
- Cancer drug shows promise against graft vs. host diseaseThu, 10 Jul 2008, 16:35:50 EDT
- Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host diseaseWed, 7 Oct 2009, 15:18:36 EDT
- Gene mismatch influences success of bone marrow transplantsSun, 22 Nov 2009, 14:50:48 EST
- Bone marrow transplant patients may benefit from new immune researchWed, 11 Feb 2009, 17:37:30 EST
- UNC study hints at new approaches to prevent transplant rejectionWed, 11 Feb 2009, 11:17:14 EST